Acrobiosystems Co

Acrobiosystems Co Working Capital Turnover

The Working Capital Turnover of Acrobiosystems Co (301080.SZ) as of Oct 20, 2026 is 4.07. In the previous year, Working Capital Turnover was 3.21 — a change of 26.78% (higher).

Working Capital Turnover

4.07

YoY

26.78%

Last updated:

Working Capital Turnover of Acrobiosystems Co is 2025 4.07 . Working Capital Turnover of Acrobiosystems Co was 2024 3.21 . It decreases by 26.78% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

Working Capital Turnover of Acrobiosystems Co is 4.07 in 2025.

Working Capital Turnover of Acrobiosystems Co changed from 3.21 to 4.07, representing a 26.78% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Working Capital Turnover Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

Working capital turnover measures how efficiently a company uses its working capital to generate revenue. Higher ratios indicate more efficient short-term asset utilization.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Working Capital Turnover's Acrobiosystems Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Working Capital Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Working Capital Turnover.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co